Retrospective analysis reveals no significant differences in comorbidities in narcolepsy patients treated vs. not treated with sodium oxybate -- -- One third of patients taking immediate-release, ...

Avadel Pharmaceuticals (AVDL) and nference announced the publication of real-world data on comorbidities and treatment patterns of people with ...

We feel now is a pretty good time to analyse Avadel Pharmaceuticals plc's ( NASDAQ:AVDL ) business as it appears ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Free Report) has been assigned an average rating of “Buy” from the eight ratings firms that are currently covering the firm, Marketbeat reports.

Avadel has initiated four patent infringement lawsuits against Jazz Pharmaceuticals since the beginning of 2025, alleging certain uses of Jazz’s Xywav product, according to its corresponding labeling, ...

Avadel Pharmaceuticals plc has a 12 month low of $6.60 and a 12 month high of $19.09. The stock has a market cap of $657.08 million, a P/E ratio of -8.61 and a beta of 1.52.

DUBLIN, April 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

DUBLIN - Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company specializing in innovative pharmaceuticals with impressive gross profit margins of 91%, announced today that patient demand for its ...

DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the ...